Hound Labs will begin delivering the HOUND ® CANNABIS BREATHALYZER in late 2022. – Keith Ward, Vice President and General Manager of Employer Solutions for Quest Diagnostics “The Hound ® solution is an important innovation because it will help employers detect and deter workday marijuana use most associated with safety risks, providing a new tool for employers to add to their suite of testing solutions.” “While marijuana use is a concern to employers focused on fostering workforce health and safety, its legalization in several states may challenge some employers struggling to hire in tight labor markets,” said Keith Ward, Vice President and General Manager of Employer Solutions for Quest Diagnostics. Quest also reported in the 2022 DTI that oral fluid positivity for marijuana increased about 20% in 2021 to 14.8% of those tested. According to the 2022 Quest Diagnostics Drug Testing Index (DTI), positivity for marijuana in urine testing for the general workforce in 2021 was 3.9%, a 20-year high. The use of cannabis has surged in recent years. Testing breath for cannabis using the HOUND ® CANNABIS BREATHALYZER isolates detection of THC to hours after use, aligning with research conducted by the University of California, San Francisco. Increasing cannabis legalization creates additional complications for employers as conventional cannabis testing methods – including oral fluid, urine, and hair – have windows of detection extending days, weeks, or months after use. French, President of Employer and Law Enforcement Solutions We are excited Quest is working with us on our mission to help employers maintain safety and promote fairness for employees.” They now need to know when an employee used cannabis to align test results more effectively with program objectives. “Cannabis legalization has prompted some employers to reconsider their workplace cannabis testing policies. French, President of Employer and Law Enforcement Solutions, with Hound Labs. “As a leader in laboratory diagnostics and workforce drug testing, Quest is ideally positioned to confirm positive results from the HOUND ® CANNABIS BREATHALYZER when our customers’ best practices require a confirmatory lab test,” said Nina M. Quest’s new technique is designed to match the level of sensitivity developed by Hound Labs to detect THC, the principal psychoactive compound in cannabis, in breath samples. Under the terms, Quest Diagnostics will use a novel mass spectrometry technique it recently developed and validated at its Lenexa, KS, laboratory to confirm positive results from the Hound ® solution. Negative test results indicate an employee is not likely to have used cannabis immediately preceding or during the workday. The HOUND ® CANNABIS BREATHALYZER, a first-of-its-kind portable solution, identifies cannabis used within hours of testing and automatically processes results on-location within minutes. The agreement establishes Quest as the exclusive provider of laboratory services for confirmatory testing of positive breath sample results generated by the HOUND ® CANNABIS BREATHALYZER, used by employers on location as an objective measure to detect and deter cannabis use during the workday. 13, 2022 – Hound Labs, a leader in ultra-sensitive, automated, accurate, and portable analytical technologies and creator of the HOUND ® CANNABIS BREATHALYZER, today announces their agreement with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services. A Quest representative told MedPage Today that the sensitivity and specificity data reported in the 2022 abstract were incorrect and the company is working to change those figures on the AAIC site.Quest to perform confirmatory testing of positive breath samples from the HOUND ® CANNABIS BREATHALYZER ![]() No peer-reviewed research papers validating the AD-Detect test have been published, but an abstract of a poster presented by Quest at the 2022 Alzheimer's Association International Conference (AAIC) provided preliminary data. ![]() ![]() They can read their test results online and have the option to speak with a physician when their results are in. ![]() Patients visit a local Quest Diagnostics lab for a blood draw. "It is not currently recommended to use Alzheimer's disease blood tests in asymptomatic individuals, as this could expose them to adverse consequences - for example, ineligibility for long-term care insurance - and they are not yet eligible for treatments," she said.Ĭonsumers pay for the $400 Quest AD-Detect test online a telehealth doctor then reviews the purchase and places an order on their behalf. Once well-validated blood-based biomarkers demonstrate equivalent performance to CSF analysis or PET scans, these recommendations may change, Schindler noted.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |